RUNX2 and acute myeloid leukemia: To evaluate whether splicing inhibition could be a potential new target in AML or could overcome cytarabine resistance, we tested several inhibitors in vitro using three different AML models of subclinical disease and stage (OCI-AML3, SKM-1 and THP-1) with different sensitivity to cytarabine.